These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

511 related articles for article (PubMed ID: 17356996)

  • 1. Variation in estimated Medicare prescription drug plan costs and affordability for beneficiaries living in different states.
    Davis MM; Patel MS; Halasyamani LK
    J Gen Intern Med; 2007 Feb; 22(2):257-63. PubMed ID: 17356996
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medicare program; Medicare prescription drug benefit. Final rule.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2005 Jan; 70(18):4193-585. PubMed ID: 15678603
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of cost sharing on prescription drugs used by Medicare beneficiaries.
    Goedken AM; Urmie JM; Farris KB; Doucette WR
    Res Social Adm Pharm; 2010 Jun; 6(2):100-9. PubMed ID: 20511109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medicare program; Medicare prescription drug discount card. Interim final rule with comment period.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2003 Dec; 68(240):69839-927. PubMed ID: 14674398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increases in Medicare prescription drug plan costs attributable to psychotropic medications.
    Zivin K; McCammon RJ; Davis MM; Halasyamani LK; Kales HC
    Am J Geriatr Psychiatry; 2008 Aug; 16(8):674-85. PubMed ID: 18669946
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost minimization of medicare part D prescription drug plan expenditures.
    Patel RA; Lipton HL; Cutler TW; Smith AR; Tsunoda SM; Stebbins MR
    Am J Manag Care; 2009 Aug; 15(8):545-53. PubMed ID: 19670958
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PDP or MA-PD? Medicare part D enrollment decisions in CMS Region 25.
    Cline RR; Worley MM; Schondelmeyer SW; Schommer JC; Larson TA; Uden DL; Hadsall RS
    Res Social Adm Pharm; 2010 Jun; 6(2):130-42. PubMed ID: 20511112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential opportunity cost of neglecting to annually reassess Medicare Part D standalone prescription drug plan offerings: the price of contentment?
    Walberg MP; Patel RA
    J Am Pharm Assoc (2003); 2009; 49(6):777-82. PubMed ID: 19926558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medicare Part D: successes and continuing challenges. Impact of Medicare Part D on Massachusetts health programs and beneficiaries.
    Thomas CP; Sussman J; ;
    Issue Brief (Mass Health Policy Forum); 2007 May; (32):1-32. PubMed ID: 17546802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Out-of-pocket health spending by poor and near-poor elderly Medicare beneficiaries.
    Gross DJ; Alecxih L; Gibson MJ; Corea J; Caplan C; Brangan N
    Health Serv Res; 1999 Apr; 34(1 Pt 2):241-54. PubMed ID: 10199672
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Falling into the doughnut hole: drug spending among beneficiaries with end-stage renal disease under Medicare Part D plans.
    Patel UD; Davis MM
    J Am Soc Nephrol; 2006 Sep; 17(9):2546-53. PubMed ID: 16855016
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How asset tests block low-income Medicare beneficiaries from needed benefits.
    Summer L; Thompson L
    Issue Brief (Commonw Fund); 2004 May; (727):1-12. PubMed ID: 15171232
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trends in the prescription drug plans delivering the Medicare Part D prescription drug benefit.
    Brill JV
    Am J Health Syst Pharm; 2007 Aug; 64(15 Suppl 10):S3-6; quiz S21-S23. PubMed ID: 17646551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Who will be denied Medicare prescription drug subsidies because of the asset test?
    Rice T; Desmond K
    Am J Manag Care; 2006 Jan; 12(1):46-54. PubMed ID: 16402888
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beneficiary price sensitivity in the Medicare prescription drug plan market.
    Frakt AB; Pizer SD
    Health Econ; 2010 Jan; 19(1):88-100. PubMed ID: 19191252
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prescription drug coverage for people with Medicare.
    Stein N
    Issue Brief Cent Medicare Educ; 2002; 3(9):1-8. PubMed ID: 12516561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Status report on Medicare Part D enrollment in 2006: analysis of plan-specific market share and coverage.
    Cubanski J; Neuman P
    Health Aff (Millwood); 2007; 26(1):w1-12. PubMed ID: 17118944
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medicare prescription drug plan costs and affordability--2007.
    Davis MM
    J Gen Intern Med; 2007 Aug; 22(8):1221-2. PubMed ID: 17497191
    [No Abstract]   [Full Text] [Related]  

  • 19. Comparison of statin adherence among beneficiaries in MA-PD plans versus PDPs.
    Jung K; McBean AM; Kim JA
    J Manag Care Pharm; 2012 Mar; 18(2):106-15. PubMed ID: 22380470
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How beneficiaries fare under the new Medicare drug bill.
    Moon M
    Issue Brief (Commonw Fund); 2004 Jun; (730):1-16. PubMed ID: 15176395
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.